Literature DB >> 18330611

Efficacy of etanercept in the treatment of a patient with Behçet's disease.

Valentina Curigliano1, Maria Giovinale, Claudia Fonnesu, Claudia Cerquaglia, Elena Verrecchia, Simona Turco, Chiara Manganelli, Raffaele Manna.   

Abstract

Behçet's disease is a systemic inflammatory disorder without a specific treatment that is chosen on the basis of the type and severity of manifestation in the organ involved. More recently, biological agents like etanercept have emerged as possible therapeutic alternatives in patients resistant to conventional therapy. We describe the successful treatment for 1 year of resistant Behçet's disease with etanercept. After the administration of this drug, a resolution of the clinical, laboratory and instrumental picture was achieved with a suspension of immunosuppressive treatments and a reduction of steroid dependency (5 mg/day). No side effects were observed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18330611     DOI: 10.1007/s10067-008-0857-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

1.  The pharmacokinetics of etanercept in healthy volunteers.

Authors:  J M Korth-Bradley; A S Rubin; R K Hanna; D K Simcoe; M E Lebsack
Journal:  Ann Pharmacother       Date:  2000-02       Impact factor: 3.154

2.  Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis.

Authors:  Howard Lee; Hui C Kimko; Mark Rogge; Diane Wang; Ivan Nestorov; Carl C Peck
Journal:  Clin Pharmacol Ther       Date:  2003-04       Impact factor: 6.875

Review 3.  Standard and novel therapeutic approaches to Behçet's disease.

Authors:  Ahmet Gul
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  New approaches in the treatment of Adamantiades-Behçet's disease.

Authors:  Nicolò Pipitone; Ignazio Olivieri; Fabrizio Cantini; Giovanni Triolo; Carlo Salvarani
Journal:  Curr Opin Rheumatol       Date:  2006-01       Impact factor: 5.006

Review 5.  Behcet's disease.

Authors:  M Suzuki Kurokawa; N Suzuki
Journal:  Clin Exp Med       Date:  2004-09       Impact factor: 3.984

Review 6.  Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.

Authors:  Honghui Zhou
Journal:  J Clin Pharmacol       Date:  2005-05       Impact factor: 3.126

Review 7.  Behçet's disease: a new target for anti-tumour necrosis factor treatment.

Authors:  P P Sfikakis
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

8.  Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Authors:  Melike Melikoglu; Izzet Fresko; Cem Mat; Yilmaz Ozyazgan; Feride Gogus; Sebahattin Yurdakul; Vedat Hamuryudan; Hasan Yazici
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

9.  Binding and functional comparisons of two types of tumor necrosis factor antagonists.

Authors:  Bernie Scallon; Ann Cai; Nancy Solowski; Amy Rosenberg; Xiao-Yu Song; David Shealy; Carrie Wagner
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

10.  Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.

Authors:  Shigeaki Ohno; Satoshi Nakamura; Sadao Hori; Machiko Shimakawa; Hidetoshi Kawashima; Manabu Mochizuki; Sunao Sugita; Satoki Ueno; Kazuyuki Yoshizaki; Goro Inaba
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666

  10 in total
  7 in total

1.  Peripheral arterial disease in patients with Behçet's disease.

Authors:  Ilknur Balta; Sevket Balta; Sait Demirkol; Ozlem Ekiz
Journal:  Rheumatol Int       Date:  2013-03-28       Impact factor: 2.631

Review 2.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 3.  Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.

Authors:  Yehyun Park; Jae Hee Cheon
Journal:  Curr Gastroenterol Rep       Date:  2020-03-19

4.  Development of Immunopathogenesis Strategies to Treat Behçet's Disease.

Authors:  Osman Köse
Journal:  Patholog Res Int       Date:  2012-04-03

Review 5.  An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.

Authors:  Thomas W McNally; Erika M Damato; Philip I Murray; Alastair K Denniston; Robert J Barry
Journal:  Orphanet J Rare Dis       Date:  2017-07-17       Impact factor: 4.123

Review 6.  Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.

Authors:  Jihye Park; Jae Hee Cheon
Journal:  Gut Liver       Date:  2018-11-15       Impact factor: 4.519

Review 7.  Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Authors:  Daniel Sánchez-Cano; José Luis Callejas-Rubio; Ricardo Ruiz-Villaverde; Raquel Ríos-Fernández; Norberto Ortego-Centeno
Journal:  Mediators Inflamm       Date:  2013-08-01       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.